Amylin's standstill agreement with Eastbourne ends; shareholder may seek increased shareholder value

By Lisa Kerner

Charlotte, N.C., Aug. 29 - Amylin Pharmaceuticals, Inc. investor Eastbourne Capital Management, LLC sold 5,965,704 shares of the company's stock on Aug. 27, the date its standstill agreement with the company automatically terminated.

The parties entered into the agreement in March in order for Eastbourne to increase its ownership position to more than 15%, according to a schedule 13D filed with the Securities and Exchange Commission.

Eastbourne, with a 12.5% stake, may now have conversations with the San Diego biopharmaceutical company's management, board of directors and other shareholders to discuss ways to maximize product sales and enhance shareholder value, the filing said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.